The Restoration of America Foundation (ROAF) is taking a strong stand regarding the abortion pill mifepristone, urging the Senate Finance Committee to hold Health and Human Services Secretary Robert F. Kennedy Jr. accountable. This call to action comes ahead of a critical hearing scheduled for Thursday at 10 a.m. In a letter obtained by Fox News Digital, ROAF raises concerns about the removal of key safety protocols that have been in place for over twenty years, arguing that this decision puts women at greater risk and shifts financial burdens onto taxpayers.
Doug Truax, the founder and CEO of ROAF, emphasized the gravity of the situation, stating, “The removal of key Risk Evaluation and Mitigation Strategy (REMS) requirements for mifepristone has eliminated essential safeguards that protected women’s health for over two decades.” His comments reflect a deep concern about how the Biden administration’s changes are impacting the safety of women seeking abortions. The loosening of previous restrictions allows for abortion pills to be prescribed through telehealth and mailed directly to patients—a shift that many consider problematic.
Previously, the FDA mandated that mifepristone be provided in person to ensure that women received proper medical screening for complications like ectopic pregnancies. This regulation was altered under the current administration, which critics argue has compromised women’s health. Truax stated, “Allowing these powerful drugs to be ordered online and sent through the mail without proper medical screening puts women at serious risk.” His urgency highlights the need for a reassessment of telehealth practices concerning such potent medication.
Issues surrounding this change are underscored by recent research and investigations, including a New York Post report from April. This report revealed that nearly 11 percent of chemical abortions resulted in significant complications, such as hemorrhage, infection, or sepsis. This alarming statistic is more than twenty times higher than the previously cited figures by the FDA, raising substantial questions about the safety of current protocols.
The upcoming Senate hearing is expected to be a focal point for broader discussions regarding abortion and medical safety, particularly in the context of the regulatory environment under the Trump administration. As Kennedy prepares to respond to these intense inquiries, the scrutiny on both the policies regarding abortion and the implications for women’s health will be significant.
The call from ROAF to reinstate safety protocols emphasizes a pressing need for dialogue about current practices surrounding the abortion pill. With serious complications emerging at alarming rates, the stakes are high. Women’s safety should be prioritized, and accountability from health officials regarding the new changes is crucial. As the debate unfolds, it becomes evident that health and safety regulations concerning reproductive choices need careful consideration and scrutiny.
"*" indicates required fields
